2Rieder M J, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose [J]. N Engl J Med, 2005 ; 352 (22) : 2285 - 2293
3Katireioglu. SF, Yamak B, Ulus AT, et al. Mitral valve replacement with St. Jude medical prosthesis and low dose anticoagulafion in patients aged over 50 years[ J]. J Heart Valve Dis, 1998 ;7:455 - 458
4Kanaoka Y, Tanemoto K, Murakami T, et al. Thromboembolic and bleeding complications in patients treated with oral anticoagulant therapy after mechanical heart valve prostheses implantation [ J ].胸部外科,2000;53(9):754-757
6Stein PD,Alpert JS,Copeland J,et al.Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.Chest,1992,102Suppl:445-455.
7Hirsh J,Dalen JE,Deykin D,et al.mechanism of a clinical effectiveness and optimal therapeutic range of oral anticoagulants.Chest,1992,102(Suppl 4):312-314.
8Horstkotte D,Schulte H,Bircks W,et al.Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10 year follow up of patients with St.Jude medical prostheses.J Heart Valve Dis,1993,2:291-293.
9Katircioglu SF,Yamak B,Ulus AT,et al.Mitral valve replacement with St.Jude medical prosthesis and low dose anticoagulation in patients aged over 50 years.J Heart Valve Dis,1998,7:455-458.
10Kanalka Y,Tanemoto K,Murakami T,et al.Thromboembolic and bleeding complications in patients treated with oral anticoagulant therapy after mechanical heart valve prostheses implantation.Kyobu Geka,2000,53:754-757.
